Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBITDA Margin (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed EBITDA Margin for 7 consecutive years, with 25348.48% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 2060007.0% year-over-year to 25348.48%; the TTM value through Mar 2026 reached 146076.47%, down 14567327.0%, while the annual FY2024 figure was 425.76%, 745479.0% up from the prior year.
  • EBITDA Margin hit 25348.48% in Q1 2026 for Barinthus Biotherapeutics, up from 1283100.0% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 117.37% in Q3 2022 and bottomed at 1283100.0% in Q2 2025.
  • Average EBITDA Margin over 5 years is 132173.7%, with a median of 1647.94% recorded in 2022.
  • On a YoY basis, EBITDA Margin climbed as much as 4820614bps in 2022 and fell as far as -166718862bps in 2022.
  • Barinthus Biotherapeutics' EBITDA Margin stood at 388.62% in 2022, then plummeted by -1303bps to 5450.6% in 2023, then surged by 100bps to 7.09% in 2024, then plummeted by -18085527bps to 1283100.0% in 2025, then soared by 98bps to 25348.48% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 25348.48%, 1283100.0%, and 4748.42% for Q1 2026, Q2 2025, and Q1 2025 respectively.